The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Open accessAbstract
A pathological hallmark of Alzheimer's disease is an accumulation of insoluble plaque containing the amyloid-beta peptide of 40-42 amino acid residues. Prefibrillar, soluble oligomers of amyloid-beta have been recognized to be early and key intermediates in Alzheimer's-disease-related synaptic dysfunction. At nanomolar concentrations, soluble amyloid-beta oligomers block hippocampal long-term potentiation, cause dendritic spine retraction from pyramidal cells and impair rodent spatial memory. Soluble amyloid-beta oligomers have been prepared from chemical syntheses, transfected cell culture supernatants, transgenic mouse brain and human Alzheimer's disease brain. Together, these data imply a high-affinity cell-surface receptor for soluble amyloid-beta oligomers on neurons-one that is central to the pathophysiological process in Alzheimer's disease. Here we identify the cellular prion protein (PrP(C)) as an amyloid-beta-oligomer receptor by expression cloning. Amyloid-beta oligomers bind with nanomolar affinity to PrP(C), but the interaction does not require the infectious PrP(Sc) conformation. Synaptic responsiveness in hippocampal slices from young adult PrP null mice is normal, but the amyloid-beta oligomer blockade of long-term potentiation is absent. Anti-PrP antibodies prevent amyloid-beta-oligomer binding to PrP(C) and rescue synaptic plasticity in hippocampal slices from oligomeric amyloid-beta. Thus, PrP(C) is a mediator of amyloid-beta-oligomer-induced synaptic dysfunction, and PrP(C)-specific pharmaceuticals may have therapeutic potential for Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the Aβ binding candidates, cellular prion protein (PrPc) represents the most studied, either alone or through a complex with mGluR5 [37, 62, 72, 79].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most studied binding partner is the PrPc, which through a cascade involving a complex with mGluR5 may lead to toxicity independently or via tau [37, 62, 72, 79].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredIn the citing paper
“Aβ binds to α7 nicotinic acetylcholine receptors (α7 nAChRs) and to metabotropic glutamate receptors, in particular mGluR5 [31–33].”
From ApoE, ApoE Receptors, and the Synapse in Alzheimer's Disease (2017) · cites this paper as [33]
In the citing paper
“A genome-wide association study (GWAS) identified PrPC as a potential high-affinity receptor for oAβ [87].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [87]
In the citing paper
“Subsequent studies showed that oAβ, especially high-molecular weight oligomers [88], preferentially bind to PrPC within an N-terminal 95-111aa segment [87].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [87]
In the citing paper
“oligomer binding is significantly reduced in PrPC knock-out cells (Lauren et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lauren et al., 2009
In the citing paper
“Aβ oligomers bind with nanomolar affinity to cellular prion protein (PrPC) and that anti-PrP antibodies reduce oligomer binding to neurons and rescue synaptic plasticity (Lauren et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lauren et al., 2009
In the citing paper
“explaining the finding that knocking-down these proteins or adding antibodies against their extracellular domains blocks the accumulation of ADDL clusters (“hotspots”) at synapses (De Felice et al., 2007; Decker et al., 2010a; Lauren et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lauren et al., 2009
In the citing paper
“PrPC binds synthetic Aβ oligomers with high affinity and plays a role in the oligomer-mediated inhibition of LTP (17).”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [17]
In the citing paper
“In an elegant study Lauren et al. (17) reported that PrPC mediates the Aβ oligomer-induced hippocampal synaptic plasticity impairment.”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [17]
In the citing paper
“The 22 °C-Aβ oligomers impaired recognition memory in both Prnp +/+ and Prnp 0/0 mice (Fig. 4C).”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [17]
In the citing paper
“When amyloid-β oligomers bind to PrPc, long-term potentiation and the formation of new memories are disrupted [129,130,131].”
From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2004) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,722
Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein
Büeler, H., Fischer, M., Lang, Y., Bluethmann, H., Lipp, H., DeArmond, S. J., Prusiner, S. B., Aguet, M., & Weissmann, C. (1992) · Nature · doi:10.1038/356577a0 · Cited by 1,676
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,002
Protection of primary neurons and mouse brain from Alzheimer's pathology by molecular tweezers
Attar, A., Ripoli, C., Riccardi, E., Maiti, P., Puma, D. D. L., Liu, T., Hayes, J. D., Jones, M. R., Lichti-Kaiser, K., Yang, F., et al. (2012) · Brain · doi:10.1093/brain/aws289 · Cited by 95
Ugalde, C. L., Finkelstein, D. I., Lawson, V. A., & Hill, A. F. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13772 · Cited by 92
Pharmacologic inhibition of LIMK1 provides dendritic spine resilience against β-amyloid
Henderson, B. W., Greathouse, K. M., Ramdas, R., Walker, C. K., Rao, T. C., Bach, S. V., Curtis, K. A., Day, J. J., Mattheyses, A. L., & Herskowitz, J. H. (2019) · Science Signaling · doi:10.1126/scisignal.aaw9318 · Cited by 94
Therapeutic potential of mGluR5 targeting in Alzheimer's disease
Kumar, A., Dhull, D. K., & Mishra, P. S. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00215 · Cited by 93
Genetic Factors in Mammalian Prion Diseases
Mead, S., Lloyd, S. E., & Collinge, J. (2019) · Annual Review of Genetics · doi:10.1146/annurev-genet-120213-092352 · Cited by 91
Tau, prions and Aβ: the triad of neurodegeneration
Reiniger, L., Lukić, A., Linehan, J. M., Rudge, P., Collinge, J., Mead, S., & Brandner, S. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0691-0 · Cited by 95
Cellular prion protein as a receptor for amyloid-β oligomers in Alzheimer's disease
Salazar, S. V., & Strittmatter, S. M. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.062 · Cited by 94
Self-citationTargeting Aβ and tau in Alzheimer's disease, an early interim report
Golde, T. E., Petrucelli, L., & Lewis, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.035 · Cited by 89
Amyloid-β-induced Synapse Damage Is Mediated via Cross-linkage of Cellular Prion Proteins
Bate, C., & Williams, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.248724 · Cited by 93
The sheddase ADAM10 is a potent modulator of prion disease
Altmeppen, H. C., Prox, J., Krasemann, S., Puig, B., Kruszewski, K., Dohler, F., Bernreuther, C., Hoxha, A., Linsenmeier, L., Sikorska, B., et al. (2015) · eLife · doi:10.7554/elife.04260 · Cited by 89
Lee, L., Sakurai, M., Matsuzaki, S., Arancio, O., & Fraser, P. E. (2013) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8257-7 · Cited by 94
Synaptic dysfunction in early phases of Alzheimer's Disease
Pelucchi, S., Gardoni, F., Luca, M. D., & Marcello, E. E. (2022) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819410-2.00022-9 · Cited by 95
A Novel Family of Negative and Positive Allosteric Modulators of NMDA Receptors
Costa, B. M., Irvine, M. W., Fang, G., Eaves, R. J., Mayo-Martin, M. B., Skifter, D. A., Jane, D. E., & Monaghan, D. T. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.174144 · Cited by 90
Ratan, Y., Rajput, A., Maleysm, S., Pareek, A., Jain, V. K., Pareek, A., Kaur, R., & Singh, G. (2023) · Biomedicines · doi:10.3390/biomedicines11051398 · Cited by 89
Haas, L. T., Kostylev, M. A., & Strittmatter, S. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.584342 · Cited by 91
Self-citationExosomes and the Prion Protein: More than One Truth
Hartmann, A., Muth, C., Dabrowski, O., Krasemann, S., & Glatzel, M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00194 · Cited by 87
Pitt, J. E., Wilcox, K. C., Tortelli, V., Diniz, L. P., Oliveira, M. S., Dobbins, C., Yu, X., Nandamuri, S., Gomes, F. C. A., DiNunno, N., et al. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-06-0416 · Cited by 87
Thal, D. R., & Tomé, S. O. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.10.006 · Cited by 92
Protein N-homocysteinylation: From cellular toxicity to neurodegeneration
Sharma, G. S., Kumar, T., Dar, T. A., & Singh, L. R. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.08.013 · Cited by 88
Pulford, B., Reim, N., Bell, A., Veatch, J., Forster, G., Bender, H., Meyerett, C., Hafeman, S., Michel, B., Johnson, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011085 · Cited by 85
EphA4 Activation of c-Abl Mediates Synaptic Loss and LTP Blockade Caused by Amyloid-β Oligomers
M. Vargas, L., Leal, N., Estrada, L. D., González, A., Serrano, F., Araya, K., Gysling, K., Inestrosa, N. C., Pasquale, E. B., & Alvarez, A. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092309 · Cited by 85
Soluble Prion Protein Inhibits Amyloid-β (Aβ) Fibrillization and Toxicity
Nieznański, K., Choi, J.-K., Chen, S., Surewicz, K. A., & Surewicz, W. K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.c112.400614 · Cited by 90
ECM in brain aging and dementia
Morawski, M., Filippov, M., Tzinia, A., Tsilibary, E., & Vargova, L. (2014) · Progress in Brain Research · doi:10.1016/b978-0-444-63486-3.00010-4 · Cited by 84
Recent Progress in Alzheimer’s Disease Research, Part 1: Pathology
Hane, F. T., Lee, B. Y., & Leonenko, Z. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160882 · Cited by 92
The Prion Protein Ligand, Stress-Inducible Phosphoprotein 1, Regulates Amyloid-β Oligomer Toxicity
Ostapchenko, V. G., Beraldo, F. H., Mohammad, A. H., Xie, Y., Hirata, P. H. F., Magalhães, A. C., Lamour, G., Li, H., Maciejewski, A., Belrose, J. C., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3214-13.2013 · Cited by 87
Pathogenesis of Abeta Oligomers in Synaptic Failure
Sivanesan, S., Tan, A., & Rajadas, J. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310030011 · Cited by 85
Singh, B., Covelo, A., Martell-Martinez, H. A., Nanclares, C., Sherman, M. A., Okematti, E., Meints, J. P., Teravskis, P. J., Gallardo, C., Savonenko, A. V., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02032-w · Cited by 85
Pfundstein, G., Nikonenko, A. G., & Sytnyk, V. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.969547 · Cited by 89
Healthy goats naturally devoid of prion protein
Benestad, S. L., Austbø, L., Tranulis, M. A., Espenes, A., & Olsaker, I. (2012) · Veterinary Research · doi:10.1186/1297-9716-43-87 · Cited by 83
Diverse functions of the prion protein – Does proteolytic processing hold the key?
Linsenmeier, L., Altmeppen, H. C., Wetzel, S., Mohammadi, B., Säftig, P., & Glatzel, M. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.06.022 · Cited by 83
Brody, A. H., & Strittmatter, S. M. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.09.007 · Cited by 89
Self-citationβ-amyloid oligomers and cellular prion protein in Alzheimer’s disease
Gunther, E. C., & Strittmatter, S. M. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0568-7 · Cited by 84
Self-citationPrion protein and Alzheimer disease
Kellett, K. A. B., & Hooper, N. M. (2009) · Prion · doi:10.4161/pri.3.4.9980 · Cited by 88
Early Life Stress and Epigenetics in Late-onset Alzheimer’s Dementia: A Systematic Review
Lemche, E. (2018) · Current Genomics · doi:10.2174/1389202919666171229145156 · Cited by 84
Hu, N., Corbett, G. T., Moore, S., Klyubin, I. V., O’Malley, T. T., Walsh, D. M., Livesey, F. J., & Rowan, M. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.040 · Cited by 84
Quintela-López, T., Ortiz-Sanz, C., Serrano-Regal, M. P., Gaminde-Blasco, A., Valero, J., Baleriola, J., Sánchez-Gómez, M. V., Matute, C., & Alberdi, E. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1636-8 · Cited by 80
Prion Protein as a Toxic Acceptor of Amyloid-β Oligomers
Purro, S. A., Nicoll, A. J., & Collinge, J. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.11.020 · Cited by 81
Smith, L. M., Kostylev, M. A., Lee, S., & Strittmatter, S. M. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006252 · Cited by 73
Self-citationAlzheimer's Disease and Amyloid: Culprit or Coincidence?
Skaper, S. D. (2012) · International review of neurobiology · doi:10.1016/b978-0-12-386986-9.00011-9 · Cited by 82
Spontaneous generation of anchorless prions in transgenic mice
Stöhr, J., Watts, J. C., Legname, G., Oehler, A., Lemus, A., Nguyen, H.-O. B., Sussman, J., Wille, H., DeArmond, S. J., Prusiner, S. B., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117827108 · Cited by 80
Amyloid-β42 Interacts Mainly with Insoluble Prion Protein in the Alzheimer Brain
Zou, W., Xiao, X., Yuan, J., Puoti, G., Fujioka, H., Wang, X., Richardson, S. L., Zhou, X., Zou, R. S., Li, S., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.199356 · Cited by 81
Liu, L., Chang, Y. K., Yu, J., Jiang, M., & Xia, N. (2017) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2017.05.106 · Cited by 80
Toyonaga, T., Smith, L. M., Finnema, S. J., Gallezot, J.-D., Naganawa, M., Bini, J., Mulnix, T., Cai, Z., Ropchan, J., Huang, Y., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.223867 · Cited by 79
Self-citationDivecha, Y. A., Rampes, S., Tromp, S., Boyanova, S., Fleckney, A. L., Fidanboylu, M., & Thomas, S. A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100052 · Cited by 83
Ojeda-May, P., & Garcia, M. E. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2010.04.040 · Cited by 79
Calderón‐Garcidueñas, L., Cross, J. V., Franco-Lira, M., Aragón-Flores, M., Kavanaugh, M., Torres‐Jardón, R., Chao, C., Thompson, C., Chang, J., Hongtu Zhu, B., et al. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00183 · Cited by 79
Pharmacological chaperone for the structured domain of human prion protein
Nicoll, A. J., Trevitt, C. R., Tattum, M. H., Risse, E., Quarterman, E., Ibarra, A. Á., Wright, C., Jackson, G. S., Sessions, R. B., Farrow, M. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009062107 · Cited by 78
Nuclear Translocation Uncovers the Amyloid Peptide Aβ42 as a Regulator of Gene Transcription*
Barucker, C., Harmeier, A., Weiske, J., Fauler, B., Albring, K. F., Prokop, S., Hildebrand, P. W., Lurz, R., Heppner, F. L., Huber, O., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.564690 · Cited by 83
Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-β-Induced Synaptic Dysfunction and Loss
Salazar, S. V., Cox, T. O., Lee, S., Brody, A. H., Chyung, A. S., Haas, L. T., & Strittmatter, S. M. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.1873-18.2018 · Cited by 77
Self-citationThe N-terminus of the prion protein is a toxic effector regulated by the C-terminus
Wu, B., McDonald, A. J., Markham, K., Rich, C. B., McHugh, K. P., Tatzelt, J., Colby, D. W., Millhauser, G. L., & Harris, D. A. (2017) · eLife · doi:10.7554/elife.23473 · Cited by 77
The Ubiquitin System in Alzheimer’s Disease
Harris, L. D., Jasem, S., & Licchesi, J. D. F. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-38266-7_8 · Cited by 79
Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis
Lavatelli, F., Imperiini, E., Orrù, S., Rognoni, P., Sarnataro, D., Palladini, G., Malpasso, G., Soriano, M. E., Fonzo, A. D., Valentini, V., et al. (2015) · The FASEB Journal · doi:10.1096/fj.15-272179 · Cited by 76
Anti-prion activity of an RNA aptamer and its structural basis
Mashima, T., Nishikawa, F., Kamatari, Y. O., Fujiwara, H., Saimura, M., Nagata, T., Kodaki, T., Nishikawa, S., Kuwata, K., & Katahira, M. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1132 · Cited by 76
Cao, Q., Shin, W. S., Chan, H., Vuong, C. K., Dubois, B., Li, B., Murray, K. A., Sawaya, M. R., Feigon, J., Black, D. L., et al. (2018) · Nature Chemistry · doi:10.1038/s41557-018-0147-z · Cited by 75
Prions and protein-folding diseases: Review: Prions and protein-folding diseases
Norrby, E. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02387.x · Cited by 75
Peptide-based electrochemical biosensing
Yuan, L., & Liu, L. (2021) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2021.130232 · Cited by 75
Haas, L. T., & Strittmatter, S. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.720664 · Cited by 75
Self-citationKlyubin, I., Nicoll, A. J., Khalili-Shirazi, A., Farmer, M., Canning, S., Mably, A., Linehan, J., Brown, A., Wakeling, M., Brandner, S., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3526-13.2014 · Cited by 74
Caetano, F. A., Beraldo, F. H., Hajj, G. N. M., Guimaraes, A. L., Jürgensen, S., Wasilewska-Sampaio, A. P., Hirata, P. H. F., Souza, I., Machado, C. F., Wong, D. Y.-L., et al. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07225.x · Cited by 74
Grochowska, K. M., Yuanxiang, P., Bär, J., Raman, R., Brugal, G. N., Sahu, G., Schweizer, M., Bikbaev, A. F., Schilling, S., Demuth, H., et al. (2017) · EMBO Reports · doi:10.15252/embr.201643519 · Cited by 75
Membrane Interactions and Toxicity by Misfolded Protein Oligomers
Gonzalez-Garcia, M., Fusco, G., & Simone, A. D. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.642623 · Cited by 73
Neurotoxic Mutants of the Prion Protein Induce Spontaneous Ionic Currents in Cultured Cells
Solomon, I. H., Huettner, J. E., & Harris, D. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.134619 · Cited by 73
P2Y4 Receptor-Mediated Pinocytosis Contributes to Amyloid Beta-Induced Self-Uptake by Microglia
Li, H.-Q., Chen, C., Dou, Y., Wu, H.-J., Liu, Y.-J., Lou, H.-F., Zhang, J.-M., Li, X.-M., Wang, H., & Duan, S. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00544-13 · Cited by 73
Involvement of Cellular Prion Protein in α-Synuclein Transport in Neurons
Urrea, L., Segura-Feliu, M., Masuda‐Suzukake, M., Hervera, A., Pedraz, L., García‐Aznar, J. M., Vila, M., Samitier, J., Torrents, E., Ferrer, I., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0451-4 · Cited by 78
AMPA Receptor Trafficking in Natural and Pathological Aging
Jurado, S. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00446 · Cited by 80
Cross Currents in Protein Misfolding Disorders: Interactions and Therapy
Morales, R., Green, K., & Soto, C. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789541998 · Cited by 72
Protective roles of Amanita caesarea polysaccharides against Alzheimer's disease via Nrf2 pathway
Li, Z., Chen, X., Zhang, Y., Liu, X., Wang, C., Teng, L., & Wang, D. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.09.216 · Cited by 72
Viles, J. H. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202215785 · Cited by 74
Turnbaugh, J. A., Unterberger, U., Saá, P., Massignan, T., Fluharty, B. R., Bowman, F. P., Miller, M. B., Supattapone, S., Biasini, E., & Harris, D. A. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1103-12.2012 · Cited by 72
Cellular Prion Protein Mediates the Toxicity of β-Amyloid Oligomers
Nygaard, H. B., & Strittmatter, S. M. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.223 · Cited by 78
Self-citationBridging Physiology and Pathology in AD
Kim, D., & Tsai, L. (2009) · Cell · doi:10.1016/j.cell.2009.05.042 · Cited by 72
Carulla, P., Bribián, A., Rangel, A., Gavı́n, R., Ferrer, I., Caelles, C., del Rı́o, J. A., & Llorens, F. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-04-0321 · Cited by 72
Causes versus effects: the increasing complexities of Alzheimer’s disease pathogenesis
Mondragón‐Rodríguez, S., Basurto‐Islas, G., Lee, H., Perry, G. L., Zhu, X., Castellani, R. J., & Smith, M. A. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.27 · Cited by 73
Cannabidiol Reverses Deficits in Hippocampal LTP in a Model of Alzheimer’s Disease
Hughes, B., & Herron, C. E. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2513-z · Cited by 72
Prions activate a p38 MAPK synaptotoxic signaling pathway
Fang, C., Wu, B., Le, N. T. T., Imberdis, T., Mercer, R. C. C., & Harris, D. A. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007283 · Cited by 74
Noncanonical Metabotropic Glutamate Receptor 5 Signaling in Alzheimer's Disease
Abd‐Elrahman, K. S., & Ferguson, S. S. G. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-021821-091747 · Cited by 73
Lourenco, M. V., Ferreira, S. T., & Felice, F. G. D. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.03.003 · Cited by 74
Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer’s disease
Yan, R., Fan, Q., Zhou, J., & Vassar, R. J. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.03.025 · Cited by 71
Bruno, V., Caraci, F., Copani, A., Matrisciano, F., Nicoletti, F., & Battaglia, G. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.044 · Cited by 73
Fu, Y., Zhao, J., Atagi, Y., Nielsen, H. M., Liu, C.-C., Zheng, H., Shinohara, M., Kanekiyo, T., & Bu, G. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0099-y · Cited by 69
α-Cleavage of cellular prion protein
Liang, J., & Kong, Q. (2012) · Prion · doi:10.4161/pri.22511 · Cited by 70
Solomon, I. H., Khatri, N., Biasini, E., Massignan, T., Huettner, J. E., & Harris, D. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.214973 · Cited by 70
Hamilton, A., Zamponi, G. W., & Ferguson, S. S. G. (2015) · Molecular Brain · doi:10.1186/s13041-015-0107-0 · Cited by 72
Cremades, N., & Dobson, C. M. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.07.009 · Cited by 72
Pharmacological inactivation of the prion protein by targeting a folding intermediate
Spagnolli, G., Massignan, T., Astolfi, A., Biggi, S., Rigoli, M., Brunelli, P., Libergoli, M., Ianeselli, A., Orioli, S., Boldrini, A., et al. (2021) · Communications Biology · doi:10.1038/s42003-020-01585-x · Cited by 71
Antibodies and protein misfolding: From structural research tools to therapeutic strategies
Genst, E. D., Messer, A. C., & Dobson, C. M. (2014) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.08.016 · Cited by 70
Pan, J., Han, J., Borchers, C. H., & Konermann, L. (2012) · Biochemistry · doi:10.1021/bi3002049 · Cited by 71
Haitao, D., Wang, H., Zhao, Y., Sun, D., & Xu, Z. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0156-z · Cited by 69
Pan, J., Han, J., Borchers, C. H., & Konermann, L. (2011) · Analytical Chemistry · doi:10.1021/ac200906v · Cited by 69
Vargas, L. M., Cerpa, W. F., Muñoz, F. J., Zanlungo, S., & Alvarez, A. R. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.01.023 · Cited by 71
Cellular prion protein and NMDA receptor modulation: protecting against excitotoxicity
Black, S. A. G., Stys, P. K., Zamponi, G. W., & Tsutsui, S. (2014) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2014.00045 · Cited by 68
Promiscuous Alzheimer's Amyloid: Yet Another Partner
Benilova, I., & De Strooper, B. (2013) · Science · doi:10.1126/science.1244166 · Cited by 67
Han, S.-H., Park, J.-C., & Mook-Jung, I. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.004 · Cited by 67
Prion proteins and copper ions. Biological and chemical controversies
Kozłowski, H., Łuczkowski, M., & Remelli, M. (2010) · Dalton Transactions · doi:10.1039/c001267j · Cited by 67
Noble, W. J., Garwood, C. J., & Hanger, D. P. (2009) · Prion · doi:10.4161/pri.3.2.8820 · Cited by 67
Rangel, A., Madroñal, N., Gruart, A., Gavı́n, R., Llorens, F., Sumoy, L., Torres, J. M., Delgado-Garcia, J. M., & del Rı́o, J. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007592 · Cited by 67
SIRPα polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells
Nuvolone, M., Kana, V., Hütter, G., Sakata, D., Mortin-Toth, S. M., Russo, G., Danska, J. S., & Aguzzi, A. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20131274 · Cited by 70
A Neuronal Culture System to Detect Prion Synaptotoxicity
Fang, C., Imberdis, T., Garza, M. C., Wille, H., & Harris, D. A. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005623 · Cited by 67
Bres, E. E., & Faissner, A. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00031 · Cited by 73
Signaling effect of amyloid-β42 on the processing of AβPP
Tabaton, M., Zhu, X., Perry, G. L., Smith, M. A., & Giliberto, L. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.002 · Cited by 74
Metadata
- Authors
- Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M.
- Affiliations
- Yale University (US)
- Corresponding author
- Strittmatter, Stephen M.
- Venue
- Nature
- Published
- 2009-02
- Volume
- 457
- Issue
- 7233
- Pages
- 1128-1132
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2748841
- OpenAlex
- W2171526610
- Cited by
- 1,560
- References
- 37
- Citations by year
- 2026: 46 · 2025: 45 · 2024: 50 · 2023: 52 · 2022: 87 · 2021: 82 · 2020: 85 · 2019: 71 · 2018: 108 · 2017: 117 · 2016: 103 · 2015: 98 · 2014: 104 · 2013: 116 · 2012: 119
- FWCI
- 87.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- U.S. Public Health Service (5T32GN07205)
- National Institute on Drug Abuse (P30DA018343)
- National Institute of Neurological Disorders and Stroke (R01NS042304, R01NS039962, R37NS033020)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- cellular prion protein, amyloid-beta oligomers, Alzheimer's disease, synaptic plasticity, long-term potentiation, cell surface receptors, lipid rafts, hippocampus, anti-PrP antibodies, prion disease, expression cloning, neurotoxicity, spatial memory, neuroprotection, neurodegeneration
- MeSH terms
- Alzheimer Disease, Amyloidosis, Animals, Chlorocebus aethiops, Hippocampus, Humans, Mice, Inbred C57BL, Neuronal Plasticity, Neurons, Peptide Fragments, Prions, Protein Binding, Receptors, Cell Surface, Synapses, Amyloid beta-Peptides, Long-Term Potentiation, COS Cells, Mice, Amyloid Precursor Protein Secretases, Protein Multimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
